We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 125

Brexit: Life Sciences implications
  • Bird & Bird
  • European Union, United Kingdom
  • August 23 2016

On 23 June 2016, the UK public voted to leave the EU. Under Article 50 of the Lisbon Treaty, the EU Treaties shall cease to apply to the UK: from the


UK Patents Court judgment in Dr Reddy’s Laboratories v Eli Lilly
  • Bird & Bird
  • United Kingdom
  • December 31 2008

In a judgment handed down in October of this year, the Patents Court (Mr Justice Floyd) upheld EP (UK) 0,454,436 (the “Patent”) which is owned by Eli Lilly and which protects the schizophrenia drug olanzapine


Corevalve Inc. v. Edwards Lifesciences AG & Edwards Lifesciences PVT, Inc
  • Bird & Bird
  • United Kingdom
  • March 11 2009

Edwards Lifesciences, the world leader in replacement heart valves, succeeded in upholding the validity of their patent for a transcatheter valve


Confidentiality in clinical trials
  • Bird & Bird
  • Netherlands
  • October 16 2008

Confidentiality covering clinical trials is important in the context of obtaining patent protection for an invention that is the subject of a clinical trial


Proposed reform of the generic substitution regime
  • Bird & Bird
  • Finland
  • October 16 2008

A recent governmental Bill has set out proposals for the introduction of a reference price system for medicinal products in Finland and for generic substitution to be extended to include pharmaceutical products that were excluded from the scope of generic substitution by amendment of the Medicines Act in 2006


Confidentiality in clinical trials
  • Bird & Bird
  • Netherlands
  • October 30 2008

Confidentiality covering clinical trials is important in the context of the obtaining patent protection for an invention that is the subject of a clinical trial


Extension of generic substitution and introduction of a reference price system in 2009
  • Bird & Bird
  • Finland
  • December 31 2008

A number of blockbusters will become subject to generic substitution in Finland earlier than in many other European countries, i.e. whilst valid product patents are still in force in other European countries


Generics in France: towards an exemption from trade mark rights and a two-tier system?
  • Bird & Bird
  • France
  • December 15 2009

On 26 November 2009, the French Senate voted on the law on ‘Financing the National Social Security for 2010’


Does requesting and receiving approval for a pharmaceutical create a threat of patent infringement? A German perspective
  • Bird & Bird
  • Germany
  • February 28 2008

Under German law, neither the application for a marketing approval nor obtaining it constitutes a ‘use’ act under Section 9 German Patent Act


Leo v Sandoz UK Patents Court finds pseudopolymorph patent valid
  • Bird & Bird
  • United Kingdom
  • July 17 2009

In his judgment of 15 May 2009 Mr Justice Floyd considered novelty and obviousness attacks on Leo Pharma’s European Patent (UK) 0,679,154 directed to the monohydrate pseudopolymorph of the vitamin D analogue calcipotriol, which is used in the topical treatment of psoriasis